Conditions: Plaque Psoriasis
Keywords: Phase 2 randomized double-blind placebo plaque psoriasis safety efficacy JAK janus kinase moderate severe
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 59
Healthy volunteers: no

Brief summary:
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.

Detailed description:

Arms:
arm 1: 200mg of PF-04965842 twice daily arm 2: 400mg of PF-04965842 once daily arm 3: 200mg of PF-04965842 once daily arm 4: Placebo comparator daily

Interventions: intervention 1: PF-04965842 intervention 2: PF-04965842 intervention 3: PF-04965842 intervention 4: Placebo
Intervention descriptions: intervention 1: Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks intervention 2: Subjects will receive 400 mg PF 04965842 daily for 4 weeks intervention 3: Subjects will receive 200 mg PF 04965842 daily for 4 weeks intervention 4: Subjects will receive placebo for 4 weeks

Protocol document: